Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate the safety and reactogenicity of the H1N1 candidate vaccine in terms of solicited local and general symptoms, unsolicited adverse events (AEs) and serious adverse events (SAEs) two weeks post Dose 1.
Critère d'inclusion
- Immunisation against A/California/7/2009 (H1N1)v-like influenza in male and female children aged 8 to 12 weeks